05/09/2008 - Loretta M. says she is sure she was given Trasylol during her open heart surgeries because her doctor spoke about using blood-regulating drugs during surgery. She had two open heart surgeries and experienced serious side effects after both. Like many people, Loretta is upset that Trasylol was used despite the risks associated with the drug. More>>>

05/06/2008 - As Bayer AG continues to study the results of the Canadian BART trial on Trasylol, and whether or not those findings may compel the manufacturer to lobby health regulators as to the merits of re-marketing a now-vilified drug, its legal arm prepares for its day in court as lawsuits against Bayer mount. More>>>

04/29/2008 - Mark L. suffered kidney failure shortly after his open heart surgery. However, he does not know for sure if Trasylol was used. Mark is now trying to determine whether or not doctors gave him Trasylol to stop him from bleeding during surgery. More>>>

04/25/2008 - Germany's Bayer AG is facing 78 lawsuits in the United States linked to its Trasylol drug used to stem bleeding during open heart surgery, its chief executive said on Friday. More>>>

04/23/2008 - Eight lawsuits filed in a Florida federal court are seeking damages from Bayer AG over a controversial anti-bleeding drug. More>>>

04/20/2008 - Pharmaceutical giant Bayer AG has announced that it is withdrawing its drug Trasylol from the market in response to a request by the FDA, in the face of increasing evidence that the drug increases patients' risk of death. More>>>

04/20/2008- When Bayer AG convenes its annual stockholder's meeting on April 25th in Cologne, the German group Coalition against BAYER Dangers (CBG) will be on hand to introduce countermotions to the proceedings, one of which will focus on the history, and dangers of Trasylol (known as Aprotinin). More>>>

04/13/2008- Alice G. says that in the six years since her mother died, her family has struggled to understand what happened. With the recent news about Trasylol, Alice says she may have a better understanding of why her mother died. More>>>

03/29/2008- Bayer AG said that a new trial on Trasylol had to be halted because the risk of death increased due to excessive bleeding. In addition to this new trial, previous studies have shown that Trasylol has a strong link to kidney failure in patients administered the drug when undergoing heart bypass surgery. More>>>

03/14/2008 - Can you imagine what would happen if three jumbo jets crashed in one month? A thousand people dead. Uproar at the FAA. Planes grounded. Immediate comprehensive inspections of all aircraft. Congressional hearings and investigations. Everything possible would be done to immediately assure public safety. More>>>

02/27/2008 - Congress got an earful today as it held hearings on legislation that would provide more funding and authority to the Food and Drug Administration (FDA). More>>>

02/26/2008 — Two studies published in the New England Journal of Medicine have linked the drug Trasylol, used to reduce bleeding during open-heart surgery, to an increased risk of death and kidney damage among other concerns. More>>>

02/26/2008 — A recent study found that patients that received Bayer's Trasylol during heart surgery were significantly more likely to die within the next decade. More>>>

02/19/2008 — We got a free preview of plaintiffs' opening statement when "60 Minutes," following its victims-and-villains storyline, makes much of the fact Bayer didn't reveal the existence of an unfavorable Trasylol study to the FDA at a September 21 advisory committee meeting. More>>>

02/17/2008 —This is the story of a drug that was on the market for 14 years and may have contributed to the deaths of thousands of patients. Trasylol, made by Bayer, is given in the operating room to control bleeding. It was a big money maker. More>>>

02/15/2008 —The lives of 22,000 patients could have been saved if U.S. regulators had been quicker to remove a Bayer AG drug used to stem bleeding during open heart surgery, according to a medical researcher interviewed by CBS Television's 60 Minutes program. More>>>

02/15/2008 — A renowned researcher calculates that 22,000 patients could have been saved if the Food and Drug Administration removed the heart surgery drug Trasylol two years ago, when his study revealed widespread death associated with it. More>>>

02/11/2008 - The risk of renal dysfunction after aprotinin (Trasylol) was used during heart surgery appears limited to patients also given ACE inhibitors during an off-pump bypass, suggested a retrospective analysis here. More>>>

02/11/2008 - A new retrospective analysis of patients undergoing CABG in whom the antifibrinolytic aprotinin (Trasylol, Bayer) was used has found that the product appears to be safe during on-pump CABG surgery. More>>>

02/08/2008 - Bayer AG's Trasylol, an anti-bleeding drug that was pulled off the market last year, is safe when used during a certain type of cardiac surgery, researchers said. More>>>

02/07/2008 - The blood saving-drug aprotinin appears safe during on-pump cardiac surgery. However, the combination of aprotinin and angiotensin-converting enzyme (ACE) inhibitors during off-pump cardiac surgery is associated with a significant risk of postoperative renal dysfunction. More>>>

12/21/2007 - The licence for Trasylol (aprotinin) has been suspended on the advice of the Commission on Human Medicines (CHM). Global marketing of the drug had already been suspended voluntarily by the marketing authorisation holders (Bayer plc and Nordic Pharma) due to safety concerns.

More>>>

11/29/2007 - The UK's Commission on Human Medicines (CHM) says that the UK marketing authorisation for Bayer AG's (NYSE:BAY) Trasylol, the anti-bleeding drug, should be suspended pending the outcome of a full Europe-wide review of the balance of risks and benefits. More>>>

11/23/2007 - Just a few weeks after Bayer decided to halt global marketing of Trasylol, advisors to Europe’s regulators has issued a statement saying that the blood loss agent should indeed be pulled. More>>>

11/18/2007 - The Food and Drug Administration has tallied at least 235 reports of deaths linked to the blood-clotting drug Trasylol, officials told The Post. More>>>

11/09/2007 - The German pharmaceutical giant Bayer AG announced this week that it would withdraw its controversial heart surgery drug, Trasylol, from the market, after studies found that the use of this drug increased heart surgery death rates by 50 percent. Thus, Trasylol has been added to a mounting pile of banished products, including the once-popular pain reliever Vioxx. More>>>

11/08/2007 - Bayer is suspending global marketing of its clotting drug Trasylol as the FDA waits for additional data from a study that suggested the drug was associated with an increased risk of death. More>>>

11/08/2007 - The German pharmaceutical giant Bayer AG announced this week that it would withdraw its controversial heart surgery drug, Trasylol, from the market, after studies found that the use of this drug increased heart surgery death rates by 50 percent. More>>>

11/07/2007 - Local heart surgeons were unwilling yesterday to dismiss the usefulness of the anti-bleeding drug that was withdrawn from the market earlier this week, though they said they have used it only in rare cases. More>>>

11/06/2007 - FDA announced that, at the agency's request, Bayer Pharmaceuticals Corp. has agreed to a marketing suspension of Trasylol (aprotinin injection), a drug used to control bleeding during heart surgery, pending detailed review of preliminary results from a Canadian study that suggested an increased risk for death. More>>>

11/06/2007 - Under pressure from government regulators around the world, Bayer announced yesterday that it is suspending global sales of a drug widely used to control bleeding during heart surgery, after a study found that patients receiving the medication were at increased risk of dying compared with those who received two other drugs. More>>>

11/06/2007 - Germany's Bayer has temporarily suspended global sales of its anti-bleeding drug Trasylol, which has been linked to a higher risk of death, pending final results of a Canadian study on the medicine. More>>>

11/05/2007 - The U.S. Food and Drug Administration (FDA) today announced that, at the agency's request, Bayer Pharmaceuticals Corp. has agreed to a marketing suspension of Trasylol, a drug used to control bleeding during heart surgery More>>>

11/05/2007 - Pressured by drug regulators from around the world, Bayer announced today that it had agreed to withdraw its controversial heart surgery drug Trasylol after a Canadian study found that it may increase the risk of death. More>>>

11/05/2007 - The U.S. Food and Drug Administration has temporarily halted the use ofthe drug Trasylol, which is used to control bleeding during heart surgery. More>>>

11/05/2007 - Bayer AG, Germany's largest drugmaker, will stop selling its Trasylol bleeding treatment after a study linked the product to a higher risk of death than competitors. More>>>

11/05/2007 - Bayer AG will take its blood-clotting injection Trasylol off the shelves from U.S. stores after the Food and Drug Administration announced that it will reexamine the drug's side effects, according to published reports Monday. More>>>

11/05/2007 - Bayer AG said it will temporarily suspend the sale of blood-clotting injection Trasylol worldwide, after a study in Canada was interrupted last month because experts said the drug exposed trial participants to an increased risk of death. More>>>

11/05/2007 - Following consultation with the German Federal Institute for Drugs and Medical Devices (BfArM), the U.S. Food and Drug Administration (FDA), Health Canada, and other health authorities, Bayer announced today that it has elected to temporarily suspend worldwide marketing of Trasylol More>>>

10/27/2007 - FDA issued an Early Communication about an Ongoing Safety Review of Aprotinin Injection (marketed as Trasylol), a drug used to control bleeding during heart surgery. More>>>

10/27/2007 - Heart surgery antifibrinolytic drug Trasylol, used to control bleeding in high risk surgery patients, has been halted. More>>>

10/27/2007 - Only last month the US Food and Drug Administration (FDA) panel had suggested that aprotinin, sold by Bayer AG under brand name Trasylol, be allowed to remain in market despite reports of increased risk of death and other serious side effect. More>>>

10/27/2007 - The Food and Drug Administration (FDA) has issued a statement informing that the antifibrinolytic drug, Trasylol (aprotinin), appears to increase the risk of death. More>>>  

10/26/2007 - A Canadian trial involving the antifibrinolytic drug Trasylol (aprotinin), used to control bleeding in high risk heart surgery patients has been halted. More>>>

10/26/2007 - Excess 30-day mortality in the aprotinin (Trasylol) arm of an ongoing heart surgery trial discovered by an interim safety analysis has forced researchers to shut down the aprotinin arm of the trial. More>>>

10/26/2007 - Today Bayer announced new guidance to physicians and health care providers regarding the use of Trasylol® (aprotinin injection) in patients at an increased risk of blood loss and blood transfusion undergoing coronary artery bypass graft (CABG) surgery with cardiopulmonary bypass (CPB). More>>>

10/26/2007 - Bayer AG, one of the world’s leading healthcare and medical product manufacturer on Thursday issued fresh guidelines to physicians for its anti-clotting drug Trasylol, after BART Executive Committee halted its Canadian trial over concerns of increased mortality risk. More>>>

10/26/2007 - Drug giant Bayer Inc. confirmed Thursday that a large Canadian-led trial studying its drug Trasylol (aprotinin) has been halted because of concerns the drug increased the risk of death among people who received it.  More>>>

10/25/2007 - Trasylol, a clotting drug used to prevent excessive bleeding during heart bypass surgery, increases the risk of death when compared with other drugs, the U.S. Food and Drug Administration (FDA) warned Thursday. More>>>

10/25/2007 - Increasing mortality throughout the first 30 days of a randomized trial among surgical patients who received aprotinin (Trasylol, Bayer), compared with other antifibrinolytic agents, has put the brakes on further enrollment, announced the US Food and Drug Administration, which said it received the news on October 19, 2007 from the study's data safety monitoring board. More>>> t the drug may present an untoward risk have been reported frequently.

10/25/2007 - U.S. regulators on Thursday said a trial of Bayer AG's heart surgery drug Trasylol found an increased risk of death from bleeding linked to the treatment. More>>>

10/25/2007 - Bayer Thursday said it issued additional guidance to physicians on Trasylol after the BART Executive Committee halted a Canada-based trial being conducted in cardiac surgery patients. More>>>

10/25/2007 - The US Food and Drug Administration said it will re-evaluate Bayer AG's (NYSE:BAY) Trasylol blood-clotting injection after an independent panel on drug safety warned it of an increased risk of death from the drug. More>>>

10/25/2007 - The U.S. Food and Drug Administration has revealed that the safety board overseeing a large Canadian-led trial has recommended the trial be stopped because of concerns the drug being tested increases the risk of death. More>>>

10/25/2007 - On October 19, 2007, FDA was notified of the Data Safety Monitoring Board’s (DSMB) recommendation to stop patient enrollment in the aprotinin (marketed as Trasylol by Bayer, Inc.) More>>>

10/21/2007 - Joseph Randone suffered a horrible death because pharmaceutical giant Bayer Corp. hid the lethal side effects of its highly profitable heart-surgery drug, a new suit alleges. More>>>

09/27/2007 - The U.S. Food and Drug Administration has recommended that additional clinical trials be conducted on a drug used locally in heart surgeries after finding patients who took it had a higher risks of serious side effects including kidney problems, heart attacks and strokes. More>>>

09/18/2007 - Largely as a result of high-profile drug safety problems such as Vioxx and Avandia, House and Senate versions of the reauthorization of the Prescription Drug Fee Users Act contain key provisions about post-market studies, the registration of clinical trials and the public release of clinical trial results. More>>>

09/12/2007 - Bayer AG's heart surgery drug, Trasylol, linked in some studies with an increased risk of death, should remain on the market, advisors to the U.S. Food and Drug Administration said on Wednesday. More>>>

09/12/2007 - Bayer’s Trasylol (aprotinin), which surgeons say is appropriate in select patients, is nevertheless under the microscope of an FDA advisory committee today regarding safety issues.

More>>>

09/10/2007 - Bayer AG's heart surgery drug Trasylol appears to increase the risk of kidney failure and the risk of death, U.S. regulators said in documents released on Monday. More>>>

09/10/2007 - FDA regulators said that Bayer's injectable Trasylol, used to control bleeding in bypass surgery, raised the risk of kidney damage in clinical studies and may also increase the chance of death in patients. More>>>

09/10/2007 - A Bayer Pharmaceuticals drug used to control bleeding in patients undergoing heart bypass surgery will face a second safety review by a Food and Drug Administration panel Wednesday. More>>>

08/17/2007 - Bayer's failure to supply U.S. regulators with risk data for heart-surgery drug Trasylol was the result of misjudgement, not a cover-up, an independent counsel hired by the German drugmaker said. More>>>

08/04/2007 - When William "Sonny" Morrill went in for heart bypass surgery, his wife was so sure he would recover she bought him new pajamas. But three days after the operation, the 61-year-old Sarasota resident died from kidney failure and a triple whammy of heart attacks. More>>>

02/10/2007 - A drug widely used to prevent excessive bleeding during heart surgery appears to raise the risk of dying in within five years by nearly 50 percent, an international study found. More>>>

02/09/2007 - Patients undergoing cardiac surgery who are given a drug widely used to limit blood loss are almost 50per cent more likely to die than those who do not receive the drug. More>>>

Ennis & Ennis, P.A. is representing individuals that have been harmed as a result of Trasylol side effects. If you or a loved one have suffered as a result of Trasylol side effects such as kidney failure, heart attack, or stroke you may be entitled to compensation. For more information about a Trasylol lawsuit, a possible Trasylol recall, or for questions regarding Trasylol class action lawsuits click here for a free, confidential case evaluation.